## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide` v13 · content_hash `17cdf376e1e7ba31…` · thread_head genesis · 2 DIVs
- **thesis (rc-mech):** Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).
  - rc-mech2 [mechanistic/active] Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.
  - rc-obesity [human/active] In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo,
  - rc-t2d [human/active] In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.
  - rc-safety [human/active] Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-ter
  - rc-phase3 [system/active] The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.
  - rc-ruo [system/active] This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide`
- **title:** Retatrutide
- **url:** https://miscsubjects.com/a/retatrutide
- **register:** essay
- **updated:** 2026-07-24T17:41:58.775Z
- **tags:** peptide, retatrutide, glp-1, obesity, disc

## Body

Retatrutide is an investigational once-weekly injection from Eli Lilly that hits three hormone receptors at once — GLP-1, GIP, and glucagon. In its Phase 2 obesity trial the top dose produced a 24.2% average weight loss at 48 weeks, the largest ever reported for a drug alone, and the curve had not flattened. It is the newest and strongest member of the incretin class, it is not approved or for sale anywhere yet, and it keeps appearing in conversations about spinal discs for one concrete reason: body weight is a load a disc has to carry, and Lilly is already trialing this drug for knee osteoarthritis, sleep apnea, and — directly relevant — chronic low back pain. This page is the full picture: the three-receptor mechanism, the exact efficacy and dosing, the adverse events with real numbers, the striking liver-fat data, how it compares to semaglutide and tirzepatide, the muscle-loss question, and the honest version of the spine argument. Zero prior knowledge assumed.

## Three receptors, one bet

Tirzepatide already showed what happens when you agonize GLP-1 and GIP together: appetite falls, the stomach empties slower, people eat less. Retatrutide adds the glucagon receptor, which does the opposite of what a diabetes-adjacent drug "should" — it raises energy expenditure and pushes the liver to burn fat. So the molecule works both ends at once: less energy in, more energy out, from one weekly shot. A 2025 review called it, without much hedging, a game-changer in obesity pharmacotherapy.

[[embed:source:s5]]

The glucagon arm is also the double-edged part. It is what makes retatrutide potentially stronger on fat loss, and it is the receptor that most demands the careful Phase 3 safety read — glucagon nudges heart rate and glucose output — which is part of why the program is so large.

## The number that got everyone's attention

The Phase 2 obesity trial ran 48 weeks. Least-squares mean weight change by dose: −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% at 12 mg. At that top dose, everyone lost at least 5%, 93% lost ≥10%, 83% lost ≥15%, about half lost ≥25%, and a quarter lost ≥30%. Critically, the trajectory had not plateaued at 48 weeks — implying more loss with longer treatment, which Phase 3 later bore out (~28% at 80 weeks).

[[embed:source:s4]]

It is disproportionately fat, too: a body-composition substudy in type 2 diabetes found retatrutide cut total fat mass more than both placebo and dulaglutide.

[[embed:source:s6]]

## The liver result is the quiet headline

The effect on liver fat is arguably more striking than the scale number. In the Phase 2a MASLD substudy, relative liver-fat reduction at 48 weeks reached −86.0% at 12 mg, and 93% of those patients dropped to a normal liver-fat level (under 5%) versus zero on placebo. Hepatologists called it among the most potent pharmacologic liver-fat reductions ever reported — credited to the glucagon arm — and it drove a dedicated Phase 3 MASH program with biopsy endpoints.

## How it's dosed, and why the ramp is slow

Retatrutide is a subcutaneous injection once weekly (half-life ~6 days). Dosing is titrated up over months: start at 2 or 4 mg, escalate every four weeks. That slow ramp is not marketing — the adverse events cluster during escalation, and a lower 2 mg start measurably reduced them. Going too fast is how people get the GI effects that make them quit.

## The adverse events, with real numbers

The profile is the incretin-class one, dose-dependent, mostly during escalation. At 12 mg: nausea 45%, decreased appetite 29%, vomiting 19%, constipation 16%, diarrhea 15%, fatigue 10% (placebo nausea was 11%). Discontinuation for adverse events ran 6-16% versus 0% on placebo. Two glucagon-specific notes: heart rate rose dose-dependently, peaking around week 24 then declining, and despite glucagon's tendency to raise blood sugar there was no clinically significant hypoglycemia — glycemic control actually improved, with 72% of prediabetic participants returning to normal. One odder signal: cutaneous hyperesthesia (skin sensitivity) in 7% versus 1% on placebo, all mild. One acute pancreatitis case; transient liver-enzyme rise in 1%.

[[embed:source:s1]]

## How it stacks up against what's already out

The ranking tracks the receptor count. Semaglutide (one receptor, GLP-1) delivers about 15% weight loss in its obesity trial; tirzepatide (two, GLP-1/GIP) about 16-22.5%; retatrutide (three) 24.2% at 48 weeks and still falling, rising toward ~28% in Phase 3. One receptor, two, three.

[[embed:source:s3]]

The honest caveat: these are cross-trial comparisons of different durations and populations, not head-to-head. No completed head-to-head retatrutide-versus-tirzepatide obesity trial exists yet. And retatrutide is the least mature — semaglutide and tirzepatide are approved and in millions of people; retatrutide is not.

## The muscle-loss question

Every incretin drug raises it: roughly 25-40% of the weight lost across the class is lean mass, which matters for strength and for older patients. Retatrutide's body-composition data is relatively reassuring on the ratio (loss skewed to fat, comparable to the class), but because it produces the largest absolute weight loss, the absolute lean-tissue loss can still be substantial. The practical implication is the same one that matters for a spine: resistance training and adequate protein are not optional add-ons.

## Why a weight-loss drug belongs in a disc article

A herniated or degenerating lumbar disc is, mechanically, a load problem. Body weight feeds that load, and the epidemiology is causal, not just correlational: Mendelian-randomization work finds higher BMI raises the odds of disc degeneration, low back pain, and sciatica.

One caution repeated everywhere as fact: the "1 lb of body weight equals 4 lb off the spine" line is catchier than it is proven. The real 4-to-5-fold load spikes measured inside living discs come from bending and lifting — the lever arm of the trunk — not a clean body-weight multiplier. The honest claim is simpler: less body weight, less to multiply every time you bend.

That the disc angle isn't hand-waving is shown by Lilly's own program. Retatrutide is in Phase 3 not only for obesity but for knee osteoarthritis and obstructive sleep apnea — a weight-bearing joint and a mechanical airway problem — on the theory that treating the adiposity treats the complication.

[[embed:source:s8]]

And the most direct signal of all: there is a Phase 3 trial of retatrutide in chronic low back pain, expected to report in 2026. That is the closest any drug in this stack comes to a real spine trial — and it is a weight/load drug, not a disc-repair one.

## Where the evidence still stops

There is no long-term human safety record yet, no approval, and the first Phase 3 readouts (type 2 diabetes) are only now landing.

[[embed:source:s7]]

Because no product exists, unregulated "research chemical" retatrutide is sold online with no guarantee of identity, dose accuracy, or sterility — and self-titration bypasses the slow escalation that controls the GI toxicity and the glucagon-driven heart-rate effect. The disc case remains inference: weight reduction plus an adjacent knee-OA trial and a not-yet-reported back-pain trial, not a disc-repair finding.

## Proven, unproven, unknown

Proven: retatrutide produces the largest weight loss and one of the largest liver-fat reductions of any drug studied, in randomized trials, with a dose-dependent GI-and-heart-rate profile. Unproven: that it does anything for a disc beyond removing load — and even the load-to-disc benefit is inference until the low-back-pain trial reads out. Unknown: long-term safety, and whether unregulated sourcing delivers the real molecule at the stated dose.

*Not medical advice. Retatrutide is investigational and not approved for weight loss or any disc condition. Nothing here is a dosing or treatment recommendation.*


## Claims (7)

- **rc-safety** [human w=?] Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.
  - who_claims: Systematic review / meta-analysis (2025)
  - slot: limitations
  - sources: s2, s4
- **rc-phase3** [system w=?] The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.
  - who_claims: TRIUMPH registrational program
  - slot: limitations
  - sources: s8, s7
- **rc-ruo** [system w=?] This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.
  - who_claims: editorial
  - slot: limitations
- **rc-obesity** [human w=?] In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.
  - who_claims: Meta-analyses (2025)
  - sources: s3, s4
- **rc-t2d** [human w=?] In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.
  - who_claims: Phase 2 substudy (2025)
  - sources: s6
- **rc-mech** [mechanistic w=?] Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).
  - who_claims: TRIUMPH program (Eli Lilly)
  - slot: what_it_is
  - sources: s8
- **rc-mech2** [mechanistic w=?] Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.
  - who_claims: Review (2025)
  - sources: s5

## Voxel graph (7 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (10)
- chain valid: no · head: ``

### s2 · pubmed · ok
- title: Efficacy and safety of retatrutide for the treatment of obesity
- url: https://pubmed.ncbi.nlm.nih.gov/40728138/
- summary: 2025 systematic review on retatrutide safety/efficacy for obesity.
- quote: This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.
- hash: `c967d92d24a7584a`

### s3 · pubmed · ok
- title: Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/39817343/
- summary: 2025 meta-analysis showing retatrutide superior to placebo for obesity.
- quote: In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.
- hash: `5b897b8c865f133b`

### s4 · pubmed · ok
- title: Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/40291085/
- summary: 2025 meta-analysis on retatrutide for obesity treatment.
- quote: Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.
- hash: `894a8378b761e3db`

### s5 · pubmed · ok
- title: Retatrutide-A Game Changer in Obesity Pharmacotherapy
- url: https://pubmed.ncbi.nlm.nih.gov/40563436/
- summary: 2025 review on retatrutide mechanisms, efficacy, and safety.
- quote: This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.
- hash: `beaa8c68dae73046`

### s6 · pubmed · ok
- title: Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- url: https://pubmed.ncbi.nlm.nih.gov/40609566/
- summary: 2025 phase 2 substudy on retatrutide effects on body composition in T2D.
- quote: In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.
- hash: `6986319f26294637`

### s7 · pubmed · ok
- title: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
- url: https://clinicaltrials.gov/study/NCT05882045
- summary: Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.
- quote: The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.
- hash: `397ba2c51b294d91`

### s8 · pubmed · ok
- title: Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
- url: https://pubmed.ncbi.nlm.nih.gov/41090431/
- summary: Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.
- quote: Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adipos
- hash: `3f0458a22c0cf3b2`

### s1 · pubmed · ok
- title: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
- url: https://pubmed.ncbi.nlm.nih.gov/42250575/
- summary: 2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.
- quote: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
- hash: `df8055142eadabf7`

### s9 · pubmed · ok
- title: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- url: https://clinicaltrials.gov/study/NCT05936151
- summary: Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.
- quote: The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).
- hash: `3ed1814e3170f9d2`

### s10 · pubmed · ok
- title: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)
- url: https://clinicaltrials.gov/study/NCT07232719
- summary: Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.
- quote: The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.
- hash: `5991724bd0539547`

## Provenance (4 model passes)
- chain valid: yes · head: `e731c2533fc3ca33`

- populate-init · grok-4.3 · 2026-06-29T16:59 · hash `a55ac49629f9`
- sources · grok-4.3 · 2026-06-29T16:59 · hash `393d8b8d79af`
- sources · grok-4.3 · 2026-06-29T16:59 · hash `443b55fc8ece`
- voxel_divide · owner · 2026-07-17T02:41 · hash `e731c2533fc3`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide|tier|assertion`
- **iMessage ask:** `retatrutide|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*